Lifelong Management of Hypertension (Developments in Cardiovascular Medicine)

個数:

Lifelong Management of Hypertension (Developments in Cardiovascular Medicine)

  • 提携先の海外書籍取次会社に在庫がございます。通常3週間で発送いたします。
    重要ご説明事項
    1. 納期遅延や、ご入手不能となる場合が若干ございます。
    2. 複数冊ご注文の場合は、ご注文数量が揃ってからまとめて発送いたします。
    3. 美品のご指定は承りかねます。

    ●3Dセキュア導入とクレジットカードによるお支払いについて
  • 【入荷遅延について】
    世界情勢の影響により、海外からお取り寄せとなる洋書・洋古書の入荷が、表示している標準的な納期よりも遅延する場合がございます。
    おそれいりますが、あらかじめご了承くださいますようお願い申し上げます。
  • ◆画像の表紙や帯等は実物とは異なる場合があります。
  • ◆ウェブストアでの洋書販売価格は、弊社店舗等での販売価格とは異なります。
    また、洋書販売価格は、ご注文確定時点での日本円価格となります。
    ご注文確定後に、同じ洋書の販売価格が変動しても、それは反映されません。
  • 製本 Paperback:紙装版/ペーパーバック版/ページ数 268 p.
  • 言語 ENG
  • 商品コード 9789400967342
  • DDC分類 616

Full Description

In the thirty years since the advent of efTective pharmacologic treatment for hypertension, the world ofthe hypertensive has been transformed beyond recog­ nition. The first change involved only malignant hypertensives with enough residual renal parenchyma to survive. Such a hypertensive could trade inevitable renal failure - unless an intracerebral bleed occurred first - for a rigid regimen which prevented his blood pressure from destroying him but which was asso­ ciated with nearly intolerable side effects. Over the next 20 years, increasing numbers of patients with hypertension of decreasing severity were treated with drugs that had fewer and fewer side effects. In 1970, with the medical world finally ready to accept the concept, the well-known Veterans Administration Study demonstrated that morbidity and mortality could be diminished in mode­ rately hypertensive patients by antihypertensive therapy that had minimal side effects. As a result there has been a major attempt to bring everyone with elevated blood pressure under lifelong pharmacologic control. It is difficult, however, to know what levels ofblood pressure deserve treatment; many who, when therapy first became available, would not have even been considered hypertensive are now candidates for treatment. The lower the pressure, the larger the potential population to be treated, but the smaller the individual risk and hence the smaller the possible benefit. The point where decades of diminished quaiity of life from treatment begins to outweigh a possible late-life complication is yet to be de­ termined.

Contents

I. Epidemiology.- 1. Epidemiology of mild hypertension.- 2. Childhood precursors of adult hypertension.- 3. Therapeutic decisions in management of borderline hypertension.- II. Pharmacology of antihypertensive agents.- 4. Salt, diuretics and resistance to treatment.- 5. Autonomic drugs used in the treatment of the hypertensive patient with particular reference to beta-receptor blocking agents.- 6. Vasodilators and their association with remission.- III. How and whom to treat.- 7. Nonpharmacologic treatment of hypertension.- 8. The enigma of mild hypertension: how much treatment?.- 9. Antihypertensive drug interactions.- IV. Prevention of hypertension and its complications.- 10. Complications of hypertension and their relation to therapy.- 11. Heart failure and hypertension.- 12. Antiplatelet drugs.- 13. Pregnancy, oral contraceptives and hypertension.- V. Hypertension as a problem for society.- 14. Systolic hypertension in the elderly.- 15. Paramedical personnel and adherence to antihypertensive regimens.- 16. Economics of hypertension.

最近チェックした商品